Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.78 USD | +1.30% | -9.30% | -42.22% |
May. 15 | INVO Bioscience, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
Apr. 18 | Top Premarket Decliners | MT |
Financials (USD)
Sales 2022 | 822K | Sales 2023 | 3.02M | Capitalization | 3.34M |
---|---|---|---|---|---|
Net income 2022 | -10M | Net income 2023 | -8M | EV / Sales 2022 | 9.4 x |
Net Debt 2022 | 2.57M | Net Debt 2023 | 8.45M | EV / Sales 2023 | 3.9 x |
P/E ratio 2022 |
-0.47
x | P/E ratio 2023 |
-0.26
x | Employees | 28 |
Yield 2022 * |
-
| Yield 2023 |
-
| Free-Float | 99.35% |
Latest transcript on INVO Bioscience, Inc.
1 day | +1.30% | ||
1 week | -9.30% | ||
Current month | -9.30% | ||
1 month | -14.43% | ||
3 months | -35.54% | ||
6 months | -45.45% | ||
Current year | -42.22% |
Managers | Title | Age | Since |
---|---|---|---|
Steven Shum
CEO | Chief Executive Officer | 55 | 17-10-10 |
Andrea Goren
DFI | Director of Finance/CFO | 56 | 21-06-13 |
J. Chris Jensen
CTO | Chief Tech/Sci/R&D Officer | - | 20-11-30 |
Members of the board | Title | Age | Since |
---|---|---|---|
Trent Davis
BRD | Director/Board Member | 56 | 19-12-15 |
Barbara Ryan
BRD | Director/Board Member | 64 | 20-09-13 |
Corporate Secretary | 55 | 08-09-30 |
Date | Price | Change | Volume |
---|---|---|---|
24-06-07 | 0.78 | +1.30% | 72,345 |
24-06-06 | 0.77 | -1.28% | 78,672 |
24-06-05 | 0.78 | -6.65% | 117,130 |
24-06-04 | 0.8356 | -1.71% | 36,593 |
24-06-03 | 0.8501 | -1.15% | 66,490 |
Delayed Quote Nasdaq, June 07, 2024 at 04:30 pm EDT
More quotes1st Jan change | Capi. | |
---|---|---|
-42.22% | 2.97M | |
-2.26% | 187B | |
+2.05% | 110B | |
-1.31% | 69.54B | |
+14.65% | 46.37B | |
-6.69% | 46.05B | |
+7.97% | 42.54B | |
+18.60% | 30.72B | |
-6.87% | 23.32B | |
-10.63% | 22.92B |
- Stock Market
- Equities
- INVO Stock